Johnson & Johnson
1Q Revenues: $20.0 billion (+13%)
1Q Earnings: $4.4 billion (-1%)
Comments: Pharmaceutical sales were $9.8 billion in the quarter, up 19%. Domestic sales increased 10% and international sales were up 33%. Sales include the impact of Actelion Ltd. which contributed 7.6%, to worldwide operational sales growth. Remicade sales were down 17% to $1.4 billion in the quarter due to competition. Stelara sales were up 29% to $1.1 billion. Simponi sales were up 21% to $518 million. Edurant sales were up 41% to $210 million. Prezista sales were up 11% to $478 million. Invega Sustenna sales were up 15% to $696 million. Darzalex sales were $432 million, up 69%. Imbruvica sales were $587 million, up 44%. Zytiga sales were $845 million, up 62%. Velcade sales were up 12% to $313 million. Xarelto sales were $578 million, up 13%. Worldwide Consumer sales were $3.4 billion in the quarter, up 5%. Worldwide Medical Devices sales were $6.8 billion, up 7.5%.